Today In History
Robert Mushet received a patent for methods of manufacturing steel.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8178561 | Method for modulating GPR119 G protein-coupled receptor and selected compounds A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therape... | 05/15/2012 |
| 8178523 | Compounds for the treatment of hepatitis C The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. ... | 05/15/2012 |
| 8168759 | Compositions monovalent for CD28 binding and methods of use Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically bind... | 05/01/2012 |
| 8168615 | Prodrugs of piperazine and substituted piperidine antiviral agents This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R | 05/01/2012 |
| 8163921 | Hepatitis C virus inhibitors Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed. ... | 04/24/2012 |
| 8163749 | Six-membered heterocycles useful as serine protease inhibitors The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, R3 and R11 are as defined her... | 04/24/2012 |
| 8158394 | Genetically stable plasmid expressing PDH and FDH enzymes Bi-cistronic plasmids used for the expression of formate dehydrogenase (FDH) and modified phenylalanine dehydrogenase (PDHmod) are provided. ... | 04/17/2012 |
| 8153677 | Substituted pyrazolylamide compounds useful as glucokinase activators Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroary... | 04/10/2012 |
| 8150634 | Protein-ligand NOE matching for high-throughput structure determination A method of enhancing the throughput and applicability of NMR-based structure determination of protein-ligand complexes is disclosed. The method circumvents the need for protein sequence-specific resonance assignments and combines NMR data analysis and ligand dockin... | 04/03/2012 |
| 8148523 | Intermediates useful in preparing certain pyrrolotriazine compounds and a process for making the intermediates The invention relates to 4-chloro-2-iodopyrrolo[1,2-f][1,2,4]triazine, which is an intermediate useful in preparing 2,4-disubstituted pyrrolotriazine compounds, and a process for preparing said intermediate. ... | 04/03/2012 |
| 8148522 | Intermediate useful in preparing certain pyrrolotriazine compounds and a process for making the intermediate The invention relates to 2,4-dibromoropyrrolo[1,2-f][1,2,4]triazine, which is an intermediate useful in preparing 2,4-disubstituted pyrrolotriazine compounds, and a process for preparing the intermediate. ... | 04/03/2012 |
| 8148400 | Thiazolyl compounds useful as kinase inhibitors The invention provides compounds of formula II: and pharmaceutically acceptable salts thereof. The formula II thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the ... | 04/03/2012 |
| 8148396 | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrog... | 04/03/2012 |
| 8148382 | Compounds for the treatment of hepatitis C The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. ... | 04/03/2012 |
| 8148361 | Kinase inhibitors The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The Formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1 and IGFR-1, thereby making them useful as anti-c... | 04/03/2012 |
| 8148332 | Method for treating a rheumatic disease using a soluble TLA4 molecule The present invention relates to compositions and methods for treating rheumatic diseases, such as psoriasis arthropathica, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands. ... | 04/03/2012 |
| 8147818 | Hepatitis C virus inhibitors The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infec... | 04/03/2012 |
| 8143425 | Heterocyclic aromatic compounds useful as growth hormone secretagogues Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I wherein R1, R1a | 03/27/2012 |
| 8143415 | Processes for making epothilone compounds and analogs A process for making epi-epothilone compounds according to formula A.1, by reacting a compound according formula C with at least one halogenating agent followed by treatment with ... | 03/27/2012 |
| 8143414 | Hepatitis C virus inhibitors This disclosure concerns novel compounds of Formula (I) or Formula (II) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded b... | 03/27/2012 |
| 8143403 | CGRP receptor antagonists The disclosure generally relates to the novel compounds of formula I, including their salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorder... | 03/27/2012 |
| 8143288 | Inhibitors of HCV replication Compounds having the structure of formula I are described. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular can inhibit the function of the HCV NS5A protein. ... | 03/27/2012 |
| 8143244 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. ... | 03/27/2012 |
| 8143243 | Compounds for the treatment of hepatitis C The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. ... | 03/27/2012 |
| 8138215 | Hepatitis C virus inhibitors The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infec... | 03/20/2012 |
| 8138171 | Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. I. ... | 03/20/2012 |
| 8137667 | Fully human antibodies against human 4-1BB Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject compris... | 03/20/2012 |
| 8133884 | Compounds for the treatment of hepatitis C The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. ... | 03/13/2012 |
| 8129398 | HIV integrase inhibitors The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also enco... | 03/06/2012 |
| 8129367 | Compounds for the treatment of Hepatitis C The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. ... | 03/06/2012 |
| 8129114 | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least... | 03/06/2012 |
| 8124768 | 4-pyridinone compounds and their use for cancer Disclosed are compounds of Formula (I): and salts thereof. Also, disclosed are methods of using the compounds in the treatment of proliferative diseases, such as cancer, and to pharmaceutical compositions comprising at leas... | 02/28/2012 |
| 8124730 | Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v The present invention provides novel polynucleotides encoding HBMYP2X7v polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further re... | 02/28/2012 |
| 8124729 | Splice variants of human G-protein coupled receptor HGPRBMY29 (HGPRMBY29SV2) The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2.... | 02/28/2012 |
| 8124615 | Diketo substituted pyrrolo[2,3-C]pyridines Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketo fused azolopiperidine and azolopiperazine derivatives of Formula I: that possess ... | 02/28/2012 |
| 8124601 | Compounds for the treatment of Hepatitis C The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. ... | 02/28/2012 |
| 8119808 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators The invention provides for compounds of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for t... | 02/21/2012 |
| 8119658 | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrog... | 02/21/2012 |
| 8119628 | Pyrrolidine fused indolobenzadiazepine HCV NS5B inhibitors The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 02/21/2012 |
| 8119389 | strain The present invention relates to a process for preparing (2R,3S)-1-halo-2-hydroxy-3-(protected)amino-4-substituted butane comprising contacting a mutagenized Rhodococcus erythropolis having ATCC deposit no. PTA-6648 with (3S)-1-halo-2-oxo-3-(protected)amino-4... | 02/21/2012 |
